81 related articles for article (PubMed ID: 20150522)
1. Effect of a high-fat meal on the pharmacokinetics of saxagliptin in healthy subjects.
Patel CG; Zhang J; Li L; Gooding L; Croop R; Li T; Boulton DW
J Clin Pharmacol; 2010 Oct; 50(10):1211-6. PubMed ID: 20150522
[No Abstract] [Full Text] [Related]
2. Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects.
Patel CG; Kornhauser D; Vachharajani N; Komoroski B; Brenner E; Handschuh del Corral M; Li L; Boulton DW
Diabetes Obes Metab; 2011 Jul; 13(7):604-14. PubMed ID: 21332626
[TBL] [Abstract][Full Text] [Related]
3. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
Sunkara G; Sabo R; Wang Y; He YL; Campestrini J; Rosenberg M; Howard D; Dole WP
J Clin Pharmacol; 2007 Sep; 47(9):1152-8. PubMed ID: 17656620
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections.
Fura A; Khanna A; Vyas V; Koplowitz B; Chang SY; Caporuscio C; Boulton DW; Christopher LJ; Chadwick KD; Hamann LG; Humphreys WG; Kirby M
Drug Metab Dispos; 2009 Jun; 37(6):1164-71. PubMed ID: 19251818
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic study of saxagliptin in healthy Chinese subjects.
Li H; Yang L; Tou CK; Patel CG; Zhao J
Clin Drug Investig; 2012 Jul; 32(7):465-73. PubMed ID: 22668067
[TBL] [Abstract][Full Text] [Related]
6. Bioequivalence of saxagliptin/metformin immediate release (IR) fixed-dose combination tablets and single-component saxagliptin and metformin IR tablets in healthy adult subjects.
Upreti VV; Keung CF; Boulton DW; Chang M; Li L; Tang A; Hsiang BC; Quamina-Edghill D; Frevert EU; Lacreta FP
Clin Drug Investig; 2013 May; 33(5):365-74. PubMed ID: 23549864
[TBL] [Abstract][Full Text] [Related]
7. Overcoming bioanalytical challenges in an Onglyza(®) intravenous [(14)C]microdose absolute bioavailability study with accelerator MS.
Xu XS; Dueker SR; Christopher LJ; Lohstroh PN; Keung CF; Cao KK; Bonacorsi SJ; Cojocaru L; Shen JX; Humphreys WG; Stouffer B; Arnold ME
Bioanalysis; 2012 Aug; 4(15):1855-70. PubMed ID: 22943617
[TBL] [Abstract][Full Text] [Related]
8. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
He YL; Ligueros-Saylan M; Sunkara G; Sabo R; Zhao C; Wang Y; Campestrini J; Pommier F; Dole K; Marion A; Dole WP; Howard D
J Clin Pharmacol; 2008 Jan; 48(1):85-95. PubMed ID: 17986525
[TBL] [Abstract][Full Text] [Related]
9. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.
Boulton DW; Li L; Frevert EU; Tang A; Castaneda L; Vachharajani NN; Kornhauser DM; Patel CG
Clin Pharmacokinet; 2011 Apr; 50(4):253-65. PubMed ID: 21348538
[TBL] [Abstract][Full Text] [Related]
10. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Deacon CF; Holst JJ
Adv Ther; 2009 May; 26(5):488-99. PubMed ID: 19444391
[TBL] [Abstract][Full Text] [Related]
11. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Gallwitz B
IDrugs; 2008 Dec; 11(12):906-17. PubMed ID: 19051153
[TBL] [Abstract][Full Text] [Related]
12. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects.
Upreti VV; Boulton DW; Li L; Ching A; Su H; Lacreta FP; Patel CG
Br J Clin Pharmacol; 2011 Jul; 72(1):92-102. PubMed ID: 21651615
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
[TBL] [Abstract][Full Text] [Related]
14. Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers.
He YL; Flannery B; Campestrini J; Leon S; Zinny MA; Ligueros-Saylan M; Jarugula V
Curr Med Res Opin; 2008 Jun; 24(6):1703-9. PubMed ID: 18471347
[TBL] [Abstract][Full Text] [Related]
15. Influences of processed rhubarbs on the activities of four CYP isozymes and the metabolism of saxagliptin in rats based on probe cocktail and pharmacokinetics approaches.
Gao J; Shi Z; Zhu S; Li GQ; Yan R; Yao M
J Ethnopharmacol; 2013 Jan; 145(2):566-72. PubMed ID: 23207062
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic Interaction Study Between Saxagliptin and Omeprazole, Famotidine, or Magnesium and Aluminum Hydroxides Plus Simethicone in Healthy Subjects: An Open-Label Randomized Crossover Study.
Ren S; Boulton DW
Clin Pharmacol Drug Dev; 2019 May; 8(4):549-558. PubMed ID: 30500110
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects.
Ayalasomayajula SP; Dole K; He YL; Ligueros-Saylan M; Wang Y; Campestrini J; Humbert H; Sunkara G
Curr Med Res Opin; 2007 Dec; 23(12):2913-20. PubMed ID: 17931461
[TBL] [Abstract][Full Text] [Related]
18. A pharmacometric approach to quantify the impact of chronic kidney disease and hemodialysis on systemic drug exposure: application to saxagliptin.
Zhang L; Boulton DW; Pfister M
J Clin Pharmacol; 2012 Jan; 52(1 Suppl):126S-33S. PubMed ID: 22232748
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous oral therapeutic and intravenous ¹⁴C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin.
Boulton DW; Kasichayanula S; Keung CF; Arnold ME; Christopher LJ; Xu XS; Lacreta F
Br J Clin Pharmacol; 2013 Mar; 75(3):763-8. PubMed ID: 22823746
[TBL] [Abstract][Full Text] [Related]
20. Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs.
He H; Tran P; Yin H; Smith H; Flood D; Kramp R; Filipeck R; Fischer V; Howard D
Drug Metab Dispos; 2009 Mar; 37(3):545-54. PubMed ID: 19074976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
